← All trials
NCT04787991
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 9, 2021
- Primary completion
- Oct 11, 2022
- Completion date
- Oct 11, 2023
- First posted
- Mar 9, 2021
- Last posted
- Nov 1, 2021
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cancer Insight, LLCLead sponsor
- The Parker InstituteLead sponsor
- Akamis BioCollaborator
- Cancer Research InstituteCollaborator
- The Parker InstituteStudy director
- The Parker InstituteOfficial
- Bristol-Myers SquibbCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.